Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05993949 · ClinicalTrials.gov registry record · Phase 1
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
A Phase 1 study of Lymphoblastic Leukemia, sponsored by Stanford University.
- Active
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05993949: Active Phase 1 study of Lymphoblastic Leukemia, sponsored by Stanford University.
NCT05993949 is a Phase 1 study of Lymphoblastic Leukemia that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 8 participants, below the 41-participant average among 6 other Lymphoblastic Leukemia trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05993949, a Phase 1 study of Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Conditions Studied
Interventions
- DRUG Dasatinib
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05993949
The ClinicalTrials.gov registry entry for NCT05993949 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 6 other Lymphoblastic Leukemia trials with a reported enrollment target (80% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.
NCT05993949 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05993949 about?
NCT05993949 is a clinical study titled "Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia". To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
What is the current status of trial NCT05993949?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-10-02. Estimated completion is 2027-06.
What conditions does trial NCT05993949 study?
This clinical trial studies the following conditions: Lymphoblastic Leukemia.
What interventions are being tested in trial NCT05993949?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT05993949?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05993949 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
RECRUITING · Phase 1
-
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
ACTIVE NOT RECRUITING · Phase 1
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
RECRUITING · Phase 2
-
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.